BIOMAT Database Logo BIOMAT Database Logo

Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realization. 2009

David M Holtzman
Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA. holtzman@neuro.wustl.edu

UI MeSH Term Description Entries

Related Publications

David M Holtzman
Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders.
November 2001, Mechanisms of ageing and development,
David M Holtzman
Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels.
August 2018, Alzheimer's research & therapy,
David M Holtzman
Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury.
January 2004, Neurology,
David M Holtzman
Brain metabolic correlates of cerebrospinal fluid beta-amyloid 42 and tau in Alzheimer's disease.
January 2009, Dementia and geriatric cognitive disorders,
David M Holtzman
Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury.
May 2003, Neurology,
David M Holtzman
Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
January 2011, Dementia and geriatric cognitive disorders,
David M Holtzman
Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
September 2015, Brain : a journal of neurology,
David M Holtzman
Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
January 2009, European neurology,
David M Holtzman
Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
June 2007, Drugs of today (Barcelona, Spain : 1998),
David M Holtzman
Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.
February 2010, Clinical chemistry,
Copied contents to your clipboard!